HTDS: AI 评分 53/100 — AI 分析 (4月 2026)

Hard to Treat Diseases Inc. is a biopharmaceutical and vaccine manufacturer based in China, marketing its products across South Asia, Southeast Asia, Central and South America, and the Middle East. The company offers a range of biologicals, chemicals, and vaccines, including treatments for cardiovascular diseases, infections, and various other conditions.

Key Facts: AI Score: 53/100 Sector: Healthcare

公司概况

概要：

Hard to Treat Diseases Inc., based in China, develops, manufactures, and distributes biopharmaceuticals and vaccines internationally, focusing on emerging markets; its diverse product portfolio and established sales network provide a foundation for growth amidst increasing global healthcare demands, though it faces competition and regulatory hurdles common in the biotech sector.

HTDS是做什么的？

Founded in 2009 and headquartered in Shenzhen, China, Hard to Treat Diseases Inc. operates as a manufacturer, supplier, and exporter of biopharmaceuticals and vaccines. The company's product portfolio spans a range of therapeutic areas, including cardiovascular diseases, infectious diseases, and other medical conditions. Key biological products include reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection. The company also offers a variety of chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection. Furthermore, Hard to Treat Diseases Inc. produces vaccines against rabies, meningococcal disease (ACYW135), influenza, Hepatitis A, and varicella. The company distributes its products through a sales network targeting South Asia, South-east Asia, Central and South America, and the Middle East, reflecting a strategic focus on emerging markets. This diversified product offering and geographic reach aim to address unmet medical needs in regions with growing healthcare demands.

HTDS的投资论点是什么？

Hard to Treat Diseases Inc. presents an investment opportunity driven by its diverse portfolio of biopharmaceuticals and vaccines, targeting high-growth emerging markets. The company's established sales network in South Asia, South-east Asia, Central and South America, and the Middle East provides a platform for expansion. With a gross margin of 28.9% and a profit margin of 15.8%, HTDS showcases its ability to generate profit. However, the may be worth researching risks associated with operating in the highly regulated pharmaceutical industry, including potential challenges related to product approvals, competition, and intellectual property protection. The company's debt-to-equity ratio of 20.63 indicates a moderate level of financial leverage.

HTDS在哪个行业运营？

Hard to Treat Diseases Inc. operates within the global biotechnology industry, which is characterized by rapid innovation, intense competition, and stringent regulatory oversight. The industry is driven by increasing healthcare needs, aging populations, and advancements in medical technology. Key trends include the development of novel therapies, personalized medicine, and biosimilars. Hard to Treat Diseases Inc.'s focus on emerging markets positions it to capitalize on the growing demand for affordable medicines and vaccines in these regions. However, the company faces competition from both multinational pharmaceutical companies and local manufacturers.

Biotechnology

Healthcare

HTDS有哪些增长机遇？

Expanding vaccine production and distribution: The global vaccine market is projected to reach $90 billion by 2026, driven by increasing immunization rates and the development of new vaccines. Hard to Treat Diseases Inc. can leverage its existing vaccine portfolio and distribution network to capture a larger share of this market, particularly in emerging economies where access to vaccines is limited. This includes expanding its production capacity and developing new vaccines to address unmet needs.
Increasing sales of biopharmaceutical products in emerging markets: Emerging markets represent a significant growth opportunity for Hard to Treat Diseases Inc., driven by increasing healthcare expenditure and growing populations. The company can expand its sales and marketing efforts in these regions to increase the market share of its biopharmaceutical products, such as reteplase and ulinastatin. This includes establishing partnerships with local distributors and healthcare providers to improve access to its products.
Developing and launching new products: Hard to Treat Diseases Inc. can invest in research and development to develop and launch new biopharmaceutical products and vaccines. This includes focusing on therapeutic areas with high unmet needs, such as oncology, immunology, and infectious diseases. The company can also explore strategic collaborations with other biotechnology companies and research institutions to accelerate its product development pipeline. Successful new product launches will drive revenue growth and enhance the company's competitive position.
Strengthening its sales network in South Asia, South-east Asia, Central and South America, and the Middle East: Hard to Treat Diseases Inc. can further strengthen its sales network in these key regions by expanding its sales force, establishing local offices, and building relationships with key opinion leaders. This will enable the company to improve its market access and increase sales of its products. The company can also leverage digital marketing and e-commerce platforms to reach a wider customer base.
Acquiring complementary businesses and technologies: Hard to Treat Diseases Inc. can pursue strategic acquisitions to expand its product portfolio, geographic reach, and technological capabilities. This includes acquiring companies with complementary products, technologies, or distribution networks. Strategic acquisitions can accelerate the company's growth and enhance its competitive position in the global biopharmaceutical market.

Gross Margin of 28.9% indicates the company's efficiency in managing production costs.
Profit Margin of 15.8% demonstrates the company's ability to generate profit after all expenses.
Debt-to-Equity Ratio of 20.63 suggests a conservative approach to financial leverage.
Beta of 0.56 indicates lower volatility compared to the overall market.
Focus on emerging markets provides access to high-growth regions with increasing healthcare demands.

HTDS提供哪些产品和服务？

Manufactures biopharmaceuticals and vaccines.
Supplies biopharmaceuticals and vaccines.
Exports biopharmaceuticals and vaccines.
Offers biological products like reteplase (rPA) and mycobacterium vaccae.
Provides chemical products like cobratide injection and entecavir capsule.
Produces vaccines for rabies, meningococcal disease, influenza, Hepatitis A, and varicella.
Markets products through a sales network in South Asia, South-east Asia, Central and South America, and the Middle East.

HTDS如何赚钱？

Develops and manufactures a range of biopharmaceuticals and vaccines.
Sells products through a direct sales force and distribution network.
Targets emerging markets with high unmet medical needs.
Focuses on both biological and chemical products, as well as vaccines.

Hospitals and clinics in China and internationally.
Pharmacies and drugstores.
Government healthcare agencies.
Patients requiring biopharmaceutical treatments and vaccines.

Established sales network in emerging markets.
Diverse product portfolio of biopharmaceuticals and vaccines.
Manufacturing capabilities for both biological and chemical products.
Experience in navigating regulatory approvals in multiple countries.

什么因素可能推动HTDS股价上涨？

Upcoming: Potential regulatory approvals for new products in key markets.
Ongoing: Expansion of sales and marketing efforts in emerging economies.
Ongoing: Strategic partnerships with local distributors and healthcare providers.
Upcoming: Potential acquisitions of complementary businesses and technologies.
Ongoing: Investment in research and development to develop new therapies.

HTDS的主要风险是什么？

Potential: Increasing competition from generic drug manufacturers.
Potential: Changes in government regulations.
Potential: Product liability claims.
Ongoing: Economic downturns in emerging markets.
Ongoing: Currency fluctuations impacting profitability.

HTDS的核心优势是什么？

Diverse product portfolio of biopharmaceuticals and vaccines.
Established sales network in emerging markets.
Manufacturing capabilities for both biological and chemical products.
Experience in navigating regulatory approvals in multiple countries.

HTDS的劣势是什么？

Limited presence in developed markets.
Dependence on a few key products.
Potential for generic competition.
Exposure to currency fluctuations.

HTDS有哪些机遇？

Expanding into new geographic markets.
Developing new products and therapies.
Acquiring complementary businesses.
Partnering with other pharmaceutical companies.

HTDS面临哪些威胁？

Increasing competition from generic drug manufacturers.
Changes in government regulations.
Product liability claims.
Economic downturns in emerging markets.

HTDS的竞争对手是谁？

Enhance Health OptionsS — Focuses on health and wellness products. — (EHOS)
Global Explorations Inc — Operates in the exploration sector. — (GBLX)
Gastech Solutions Corp — Provides gas technology solutions. — (GSTC)
Imex Corp — Specializes in import and export services. — (IMEXF)
Irras AB — Develops innovative neurocritical care products. — (IRBS)

Key Metrics

MoonshotScore: 53/100

Company Profile

CEO: Shimin Yuan
Headquarters: Shenzhen, CN
Founded: 1998

AI Insight

AI analysis pending for HTDS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Hard to Treat Diseases Inc. do?

Hard to Treat Diseases Inc. is a biopharmaceutical company that manufactures, supplies, and exports a range of biologicals, chemicals, and vaccines. Its product portfolio includes treatments for cardiovascular diseases, infectious diseases, and other medical conditions. The company markets its products through a sales network that focuses on South Asia, South-east Asia, Central and South America, and the Middle East, targeting emerging markets with high unmet medical needs. HTDS aims to provide affordable and accessible healthcare solutions in these regions.

What do analysts say about HTDS stock?

AI analysis is currently pending for Hard to Treat Diseases Inc. Therefore, a comprehensive analyst consensus is not yet available. Key valuation metrics and growth considerations will be assessed in the pending AI analysis. Investors should conduct their own due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. The pending AI analysis will provide further insights into the company's financial performance and growth prospects.

What are the main risks for HTDS?

Hard to Treat Diseases Inc. faces several risks, including increasing competition from generic drug manufacturers, changes in government regulations, and potential product liability claims. The company also faces risks related to economic downturns in emerging markets and currency fluctuations. As an OTC stock, HTDS is subject to limited financial disclosure and regulatory oversight, increasing the risk of fraud and manipulation. Investors should carefully consider these risks before investing in HTDS.